ArQule, Inc.
(NASDAQ : ARQL)

( )
ARQL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MNKMallinckrodt Plc
-0.28%35.9721.1%$138.29m
PRGOPerrigo Co. Plc
-1.88%74.076.7%$126.06m
SHPGShire PLC Sponsored ADR
0.46%171.430.4%$113.20m
ENDPEndo International Plc
-1.95%15.608.9%$89.97m
JAZZJazz Pharmaceuticals Plc
-0.16%173.972.2%$72.74m
ICPTIntercept Pharmaceuticals, Inc.
3.50%107.0018.7%$69.26m
SAGESAGE Therapeutics, Inc.
3.81%153.879.6%$58.93m
UTHRUnited Therapeutics Corporation
2.46%128.1114.4%$52.33m
CTLTCatalent Inc
0.70%41.582.6%$48.31m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.41%137.496.8%$42.64m
PTLAPortola Pharmaceuticals, Inc.
1.20%25.327.7%$42.29m
SUPNSupernus Pharmaceuticals, Inc.
-0.11%44.356.2%$40.49m
ICLRICON Plc
1.41%143.944.2%$39.20m
ZGNXZogenix, Inc.
0.86%46.9011.9%$38.19m
HZNPHorizon Pharma plc
-0.63%20.507.4%$33.41m

Company Profile

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. The company was founded in 1993 and is headquartered in Burlington, MA.